MCID: MLG164
MIFTS: 27

Malignant Epithelial Tumor of Ovary

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Malignant Epithelial Tumor of Ovary

MalaCards integrated aliases for Malignant Epithelial Tumor of Ovary:

Name: Malignant Epithelial Tumor of Ovary 59
Ovarian Malignant Epithelial Tumor 59
Epithelial Cancer of Ovary 59
Ovarian Epithelial Cancer 59

Classifications:



External Ids:

UMLS via Orphanet 73 C0677886
Orphanet 59 ORPHA398934

Summaries for Malignant Epithelial Tumor of Ovary

MalaCards based summary : Malignant Epithelial Tumor of Ovary, also known as ovarian malignant epithelial tumor, is related to ovarian epithelial cancer and malignant non-epithelial tumor of ovary. The drugs Gemcitabine and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and bone.

Related Diseases for Malignant Epithelial Tumor of Ovary

Diseases related to Malignant Epithelial Tumor of Ovary via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 21)
# Related Disease Score Top Affiliating Genes
1 ovarian epithelial cancer 12.6
2 malignant non-epithelial tumor of ovary 11.4
3 ovary transitional cell carcinoma 11.3
4 ovarian cancer 10.5
5 serous cystadenocarcinoma 10.1
6 ovarian cyst 10.0
7 prostate cancer 9.8
8 polycystic kidney disease 4 with or without polycystic liver disease 9.8
9 ovarian cancer 1 9.8
10 endometrial cancer 9.8
11 neutropenia 9.8
12 papillary serous adenocarcinoma 9.8
13 cystadenoma 9.8
14 transitional cell carcinoma 9.8
15 endometriosis 9.8
16 adenocarcinoma 9.8
17 cystadenocarcinoma 9.8
18 ovary adenocarcinoma 9.8
19 ovarian serous cystadenocarcinoma 9.8
20 peritonitis 9.8
21 appendicitis 9.8

Graphical network of the top 20 diseases related to Malignant Epithelial Tumor of Ovary:



Diseases related to Malignant Epithelial Tumor of Ovary

Symptoms & Phenotypes for Malignant Epithelial Tumor of Ovary

Drugs & Therapeutics for Malignant Epithelial Tumor of Ovary

Drugs for Malignant Epithelial Tumor of Ovary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 315)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
4
Sodium citrate Approved, Investigational Phase 3 68-04-2
5
Tamoxifen Approved Phase 3 10540-29-1 2733526
6
Melphalan Approved Phase 3 148-82-3 460612 4053
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
10
Ondansetron Approved Phase 3 99614-02-5 4595
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
13
Ribavirin Approved Phase 3 36791-04-5 37542
14
Palivizumab Approved, Investigational Phase 3 188039-54-5
15
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
16
Captopril Approved Phase 3 62571-86-2 44093
17
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
18
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
19
Acyclovir Approved Phase 3 59277-89-3 2022
20
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
21
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
22
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
23
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
24
Bevacizumab Approved, Investigational Phase 3 216974-75-3
25
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
26
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
27
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
28
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
29
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
30
Polyestradiol phosphate Approved Phase 3 28014-46-2
31
Mycophenolic acid Approved Phase 3 24280-93-1 446541
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
33
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
34
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
35 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
36 Anti-Bacterial Agents Phase 3
37 Anti-Infective Agents Phase 3
38 Antiviral Agents Phase 3
39 Antimetabolites Phase 3
40 Antimetabolites, Antineoplastic Phase 3
41 Liver Extracts Phase 3
42 Topoisomerase Inhibitors Phase 3
43 topoisomerase I inhibitors Phase 3
44 Gastrointestinal Agents Phase 3
45 Cola Phase 3
46
Liposomal doxorubicin Phase 3 31703
47 Citrate Phase 3
48 Estrogen Receptor Antagonists Phase 3
49 Estrogen Antagonists Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 413)
# Name Status NCT ID Phase Drugs
1 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
2 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
3 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
4 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
5 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
6 Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial Completed NCT00004166 Phase 3 amifostine trihydrate
7 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
8 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
9 A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
10 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
11 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
12 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
13 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
14 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
15 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
16 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
17 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
18 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
19 A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
20 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
21 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
22 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy
23 Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III) Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
24 A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
25 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
26 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
27 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
28 A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma Completed NCT00003636 Phase 3 carboplatin;cisplatin
29 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
30 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
31 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
32 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
33 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
34 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
35 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators Completed NCT00002895 Phase 3 chemotherapy
38 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
39 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
40 A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
41 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
42 Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
43 A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer Recruiting NCT01376752 Phase 3 HIPEC
44 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
45 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
46 Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer Not yet recruiting NCT03220932 Phase 3 Chemotherapy and bevacizumab (CT-BEV)
47 A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer Suspended NCT01170650 Phase 3 EC145;Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);placebo;EC20
48 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
49 Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5) Terminated NCT00350948 Phase 3 Telcyta;Liposomal Doxorubicin
50 A Randomized Phase III Study for the Treatment of Recurrent Epithelial Ovarian Cancer: Chemotherapy Alone Versus Chemotherapy Followed by Secondary Cytoreductive Surgery in Patients With a Treatment-Free Interval of More Than 12 Months Terminated NCT00006356 Phase 3 carboplatin;cisplatin

Search NIH Clinical Center for Malignant Epithelial Tumor of Ovary

Genetic Tests for Malignant Epithelial Tumor of Ovary

Anatomical Context for Malignant Epithelial Tumor of Ovary

MalaCards organs/tissues related to Malignant Epithelial Tumor of Ovary:

41
Ovary, T Cells, Bone, Bone Marrow, Breast, Lung, Testes

Publications for Malignant Epithelial Tumor of Ovary

Articles related to Malignant Epithelial Tumor of Ovary:

(show top 50) (show all 297)
# Title Authors PMID Year
1
Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients. 38
31289467 2019
2
Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer. 38
31316041 2019
3
Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. 38
30963272 2019
4
Magnetic resonance imaging in categorization of ovarian epithelial cancer and survival analysis with focus on apparent diffusion coefficient value: correlation with Ki-67 expression and serum cancer antigen-125 level. 38
31242916 2019
5
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. 38
31208449 2019
6
Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. 38
31167492 2019
7
Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics. 38
30970615 2019
8
[Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. 38
30686727 2019
9
Detecting recurrent ovarian cancer: revisit the values of whole-body CT and serum CA 125 levels. 38
30678481 2019
10
Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. 38
30428884 2018
11
Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. 38
30059681 2018
12
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. 38
29454514 2018
13
Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors. 38
29552194 2018
14
Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis. 38
30210623 2018
15
Splenectomy during cytoreductive surgery in epithelial ovarian cancer. 38
30254490 2018
16
Stably Fluorescent Cell Line of Human Ovarian Epithelial Cancer Cells SK-OV-3ip-red. 38
29124539 2017
17
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene. 38
29034880 2017
18
The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer. 38
29028099 2017
19
(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol suppresses ovarian cancer cell growth via inhibition of ERK and STAT3. 38
28277616 2017
20
Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. 38
28693156 2017
21
Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation. 38
28685546 2017
22
[HORMONE REPLACEMENT THERAPY AFTER GYNECOLOGICAL MALIGNANCIES]. 38
28551932 2017
23
BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions. 38
28270171 2017
24
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. 38
28796802 2017
25
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. 38
29953793 2017
26
[MicroRNA Analysis in Epithelial Ovarian Cancer]. 38
28471201 2017
27
Epithelial Ovarian Cancer Diagnosis of Second-Harmonic Generation Images: A Semiautomatic Collagen Fibers Quantification Protocol. 38
28469386 2017
28
Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus. 38
27905089 2016
29
The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. 38
27792292 2016
30
Platelets are not hyperreactive in patients with ovarian cancer. 38
27185008 2016
31
Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells. 38
27714673 2016
32
Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. 38
27602775 2016
33
New halogenated constituents from Mangifera zeylanica Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells. 38
27224244 2016
34
Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma. 38
27259239 2016
35
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. 38
27017986 2016
36
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. 38
27445438 2016
37
Tumor suppressor in lung cancer 1 gene expression in epithelial ovarian cancer. 38
27146728 2016
38
Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. 38
26554540 2015
39
Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition. 38
26323892 2015
40
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. 38
26553648 2015
41
[Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells]. 38
26607088 2015
42
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. 38
26408685 2015
43
[THE EFFECT OF PLACENTAL SOLUBLE FACTORS AND STEROID HORMONES ON OVARIAN CANCER PHENOTYPE]. 38
26480610 2015
44
Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. 38
26198101 2015
45
Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. 38
25768081 2015
46
Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. 38
26137074 2015
47
Coexistence of benign struma ovarii, pseudo-Meigs' syndrome and elevated serum CA 125: Case report and review of the literature. 38
25789033 2015
48
Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis. 38
25483274 2015
49
The tumor suppressor protein p150(Sal2) in carcinogenesis. 38
25608837 2015
50
Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. 38
25609006 2015

Variations for Malignant Epithelial Tumor of Ovary

Expression for Malignant Epithelial Tumor of Ovary

Search GEO for disease gene expression data for Malignant Epithelial Tumor of Ovary.

Pathways for Malignant Epithelial Tumor of Ovary

GO Terms for Malignant Epithelial Tumor of Ovary

Sources for Malignant Epithelial Tumor of Ovary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....